N-piperidine Ibrutinib hydrochloride

Target: This ligand targets Bruton tyrosine kinase (BTK) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for Bruton tyrosine kinase (BTK). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings Bruton tyrosine kinase (BTK) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC Ligand for BTK: N-piperidine Ibrutinib hydrochloride can be used as a BTK-binding warhead in PROTAC designs to recruit E3 ligases and drive selective BTK degradation. This enables systematic evaluation of how linker length, attachment position, and E3 selection influence ubiquitination efficiency and downstream signaling suppression in BTK-dependent cellular models.

• E3-Ligase Recruitment Optimization: Incorporate this ligand into PROTAC architectures to test multiple E3 ligases and determine which recruitment strategy yields the strongest degradation over mere kinase inhibition. Researchers can compare degradation kinetics, dose–response relationships, and proteasome dependence to refine constructs for robust, sustained BTK loss in target-positive systems.

• Linker and Attachment Scanning: Use N-piperidine Ibrutinib hydrochloride to support structure–activity exploration by varying linker chemistry and the conjugation site on the BTK-binding moiety. Such studies help map steric and conformational constraints that govern ternary complex formation, thereby improving degradation potency and selectivity while minimizing off-target protein turnover.

• Mechanistic Studies of Degradation: Employ PROTACs built from this ligand to dissect the molecular requirements for BTK degradation, including ubiquitin chain formation, ternary complex stability, and dependence on the ubiquitin–proteasome pathway. These experiments can clarify whether degradation arises from efficient engagement dynamics rather than occupancy alone, guiding rational PROTAC optimization.

N-piperidine Ibrutinib hydrochloride is a BTK kinase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of N-piperidine Ibrutinib hydrochloride is characterized by primary or secondary amine/basic nitrogen centers; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.